Contrast mediums Industry Market Development Forecast (2022)

Contrast mediums Industry Market Development Forecast (2022)

Ultrasound contrast agent is a liquid containing bubbles with a diameter of a few microns. It is used to enhance the ultrasound Doppler signal of blood flow and improve the clarity and resolution of ultrasound images by injecting it into human blood vessels.
The market size of contrast agents
Public data shows that China’s contrast agent market has grown at a CAGR of 18% from 2010 to the present, and the contrast agent market in China reaches RMB 15 billion in 2021. the perfect performance of the contrast agent market is attracting the attention of the pharmaceutical industry more and more.
Diagnostic imaging is one of the most important ways of clinical diagnosis. With the advancement of ultrasound technology and the increase in the detection rate of various diseases by high-resolution ultrasound, the size of China’s ultrasound contrast agent market is expected to grow rapidly, from 190 million yuan in 2016 to 320 million yuan in 2020, and is expected to grow to 530 million yuan by 2022.
Future Development Trend of the Contrast Agents Market
From the above data, ti is easy to see that the market for contrast agents in China is expanding year by year and gaining momentum, this is mainly due to the huge demand for domestic applications and the continuous expansion of approved indications in China.
Echocardiography is currently the only visual medical imaging technology method capable of providing real-time dynamic continuous dynamic assessment of cardiac anatomy and function at the bedside, with no ionizing radiation, easy access, portability, and relatively low cost compared to other imaging technologies. Currently, there are numerous applications for bedside echocardiography in emergency diagnosis, concomitant diagnosis after postoperative medication, and diagnosis of cardiovascular diseases in intensive care units. To ensure diagnostic accuracy, ultrasound contrast agents will be more widely used in bedside ultrasound diagnosis in the future.
At present, the approved indications for ultrasound contrast agents in China are only cardiac ultrasound and liver ultrasound, and the application in non-cardiovascular fields is not deep enough, and ultrasound contrast agents will continue to expand to non-cardiovascular indications in the future.
It can be said that the market potential of Chinese contrast agents is still very huge, and pharmaceutical companies should seize the opportunity.